Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385479039> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4385479039 abstract "Abstract Background Anti-vascular endothelial growth factor (anti-VEGF) therapy is used for myopic choroidal neovascularization (mCNV). Patchy chorioretinal atrophy (pCRA) enlargement has been reported in mCNV cases associated with vision loss. Our aim was to compare the long-term effectiveness of anti-VEGF therapy alone versus anti-VEGF followed by posterior scleral reinforcement (PSR) in controlling myopic maculopathy in mCNV eyes. Methods We performed a retrospective review of the medical records of 95 high myopia patients (refractive error ≥ 6.00 diopters, axial length ≥ 26.0 mm) with mCNV. Patients were treated with anti-VEGF alone (group A) or anti-VEGF followed by PSR (group B). The following data were collected: refractive error, best corrected visual acuity (BCVA), ophthalmic fundus examination, ocular coherence tomography and ocular biometry at 12 and 24 months pre- and postoperatively. The primary outcomes were changes in pCRA and BCVA. Results In 26 eyes of 24 patients, the mean pCRA size significantly increased from baseline (0.88 ± 1.69 mm 2 ) to 12 months (1.57 ± 2.32 mm 2 , t = 3.249, P = 0.003) and 24 months (2.17 ± 2.79 mm 2 , t = 3.965, P = 0.001) postoperatively. The increase in perilesional pCRA in group B was 98.2% and 94.2% smaller than that in group A at 12 and 24 months ( Beta 0.57 [95% CI 0.01, 191 1.13], P = 0.048). In group B, 7 eyes (58.3%) gained more than 2 lines of BCVA compared with only 4 eyes (28.6%) in group A at 24 months. Conclusion Anti-VEGF therapy followed by PSR achieved better outcomes than anti-VEGF therapy alone in controlling the development of myopic maculopathy in mCNV and may constitute a better treatment option by securing a better long-term VA outcome." @default.
- W4385479039 created "2023-08-03" @default.
- W4385479039 creator A5000737891 @default.
- W4385479039 creator A5012687551 @default.
- W4385479039 creator A5041723144 @default.
- W4385479039 creator A5051317390 @default.
- W4385479039 creator A5058344902 @default.
- W4385479039 creator A5060427417 @default.
- W4385479039 creator A5070508316 @default.
- W4385479039 date "2023-08-02" @default.
- W4385479039 modified "2023-09-27" @default.
- W4385479039 title "Long-Term Outcomes of Anti-VEGF Therapy with and without Posterior Scleral Reinforcement on Myopic Maculopathy in mCNV Eyes" @default.
- W4385479039 cites W1495650034 @default.
- W4385479039 cites W1531024108 @default.
- W4385479039 cites W1929901880 @default.
- W4385479039 cites W1966944283 @default.
- W4385479039 cites W1986457383 @default.
- W4385479039 cites W1988457599 @default.
- W4385479039 cites W1995540454 @default.
- W4385479039 cites W2002934681 @default.
- W4385479039 cites W2003759790 @default.
- W4385479039 cites W2063241000 @default.
- W4385479039 cites W2064140553 @default.
- W4385479039 cites W2107751384 @default.
- W4385479039 cites W2123215356 @default.
- W4385479039 cites W2154371500 @default.
- W4385479039 cites W2163242654 @default.
- W4385479039 cites W2165577587 @default.
- W4385479039 cites W2298136344 @default.
- W4385479039 cites W2320771385 @default.
- W4385479039 cites W2543444580 @default.
- W4385479039 cites W2748001554 @default.
- W4385479039 cites W2777277887 @default.
- W4385479039 cites W2802014238 @default.
- W4385479039 cites W3028709325 @default.
- W4385479039 cites W3098991797 @default.
- W4385479039 cites W3128198827 @default.
- W4385479039 cites W3158157351 @default.
- W4385479039 cites W43396993 @default.
- W4385479039 cites W4361866471 @default.
- W4385479039 doi "https://doi.org/10.21203/rs.3.rs-3188814/v1" @default.
- W4385479039 hasPublicationYear "2023" @default.
- W4385479039 type Work @default.
- W4385479039 citedByCount "0" @default.
- W4385479039 crossrefType "posted-content" @default.
- W4385479039 hasAuthorship W4385479039A5000737891 @default.
- W4385479039 hasAuthorship W4385479039A5012687551 @default.
- W4385479039 hasAuthorship W4385479039A5041723144 @default.
- W4385479039 hasAuthorship W4385479039A5051317390 @default.
- W4385479039 hasAuthorship W4385479039A5058344902 @default.
- W4385479039 hasAuthorship W4385479039A5060427417 @default.
- W4385479039 hasAuthorship W4385479039A5070508316 @default.
- W4385479039 hasBestOaLocation W43854790391 @default.
- W4385479039 hasConcept C118487528 @default.
- W4385479039 hasConcept C141071460 @default.
- W4385479039 hasConcept C259533 @default.
- W4385479039 hasConcept C2776391266 @default.
- W4385479039 hasConcept C2778257484 @default.
- W4385479039 hasConcept C2781135284 @default.
- W4385479039 hasConcept C2781359195 @default.
- W4385479039 hasConcept C71924100 @default.
- W4385479039 hasConceptScore W4385479039C118487528 @default.
- W4385479039 hasConceptScore W4385479039C141071460 @default.
- W4385479039 hasConceptScore W4385479039C259533 @default.
- W4385479039 hasConceptScore W4385479039C2776391266 @default.
- W4385479039 hasConceptScore W4385479039C2778257484 @default.
- W4385479039 hasConceptScore W4385479039C2781135284 @default.
- W4385479039 hasConceptScore W4385479039C2781359195 @default.
- W4385479039 hasConceptScore W4385479039C71924100 @default.
- W4385479039 hasLocation W43854790391 @default.
- W4385479039 hasOpenAccess W4385479039 @default.
- W4385479039 hasPrimaryLocation W43854790391 @default.
- W4385479039 hasRelatedWork W127676077 @default.
- W4385479039 hasRelatedWork W1967904515 @default.
- W4385479039 hasRelatedWork W2058043704 @default.
- W4385479039 hasRelatedWork W2083248541 @default.
- W4385479039 hasRelatedWork W2095345573 @default.
- W4385479039 hasRelatedWork W2386587489 @default.
- W4385479039 hasRelatedWork W2396091285 @default.
- W4385479039 hasRelatedWork W2802014238 @default.
- W4385479039 hasRelatedWork W2923230500 @default.
- W4385479039 hasRelatedWork W3029119644 @default.
- W4385479039 isParatext "false" @default.
- W4385479039 isRetracted "false" @default.
- W4385479039 workType "article" @default.